J&J MedTech Joins China’s Surgical Training Program to Skill Up Surgeons
The National Institute of Hospital Administration (NIHA) and the National Health Commission (NHC) launched the...
Johnson & Johnson
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem
Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson &...
WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production
WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...
GenScript’s Legend Biotech Appoints Three New Directors to Board
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...
J&J Q2 Sales Rise 8% but Profits Plunge 23% Amid China COVID Lockdowns
US giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q2 2022 financials, showing 8.0% year-on-year...
Hangzhou DAC Bio Partners with Janssen on ADC Development Deal
China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...
Huadong Medicine’s SaiYueXin Receives NMPA Approval for Pediatric Psoriasis Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...